iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Yahoo Finance · Aug 28, 2026 · iBio, Inc. Common Stock (IBIO)
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase
Not investment advice. Cached headline, not a full reprint.